Read on Twitter
The RECOVERY Data Monitoring Committee reviewed data on patients randomised to convalescent plasma vs. usual care. The preliminary analysis based on 10,406 randomised patients with 1873 reported deaths shows no significant difference in the primary endpoint of 28-day mortality.
18% convalescent plasma vs. 18% usual care alone; risk ratio 1.04 [95% confidence interval 0.95-1.14]; p=0.34. Follow-up of patients is ongoing and final results will be published as soon as possible.
Although negative, this result is incredibly important and moves forward the treatment of COVID. This was only possible thanks to the generosity of recovered patients and the willingness of current patients to contribute to advancing medical care. We owe you all a great debt.
And of course the many thousands of staff in the NHS, NIHR and the blood transfusion services. Whilst the overall result is negative, we need to await the full results before we can fully understand whether convalescent plasma has any benefit in particular patient subgroups.
We also continue to study REGN-CoV2, tocilizumab, aspirin and colchicine.
